New agents for the treatment of patients with acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 3, Issue 3, 2008, Pages 135-143

  DeAngelo, Daniel J ^a   Stone, Richard M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALEMTUZUMAB; ASPARAGINASE; BOSUTINIB; CLOFARABINE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; EPRATUZUMAB; FOLIC ACID ANTAGONIST; FORODESINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHOTREXATE; NELARABINE; NILOTINIB; NUCLEOSIDE ANALOG; PANOBINOSTAT; PEMETREXED; PHA 739538; PRALATREXATE; PT 525; RITUXIMAB; ROMIDEPSIN; TALOTREXIN; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ALLERGIC REACTION; ANOREXIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INHIBITION; FEBRILE NEUTROPENIA; HUMAN; HYPOTENSION; LIPID METABOLISM; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ASPARAGINASE; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIPOSOMES; METHOTREXATE; NUCLEOSIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, NOTCH; RECURRENCE;

EID: 47549116405     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0020-z     Document Type: Review

References (64)

1. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
2. Larson RA, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85:2025-2037.
3. Larson RA, Dodge RK, Linker CA, et al.: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998, 92:1556-1564.
4. Stock W, Johnson J, Yu D, et al.: Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): final results from Cancer and Leukemia Group B Study 19802 [abstract]. Blood 2005, 106:521a.
5. Kantarjian H, Thomas D, O'Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788-2801.
6. Fielding AK, Richards SM, Chopra R, et al.: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
7. Le QH, Thomas X, Ecochard R, et al.: Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial. Cancer 2007, 109:2058-2067.
8. Thomas DA, Kantarjian H, Smith TL, et al.: Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999, 86:1216-1230.
9. Jeha S, Gandhi V, Chan KW, et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
10. Jeha S, Gaynon PS, Razzouk BI, et al.: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006, 24:1917-1923.
11. Kantarjian HM, Gandhi V, Kozuch P, et al.: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
12. Kantarjian H, Gandhi V, Cortes J, et al.: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379-2386.
13. Faderl S, Gandhi V, O'Brien S, et al.: Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005, 105:940-947.
14. Faderl S, Verstovsek S, Cortes J, et al.: Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006, 108:45-51.
15. DeAngelo DJ, Yu D, Johnson JL, et al.: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007, 109:5136-5142.
16. Kisor DF, Plunkett W, Kurtzberg J, et al.: Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000, 18:995-1003.
17. Kurtzberg J, Ernst TJ, Keating MJ, et al.: Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005, 23:3396-3403.
18. Berg SL, Blaney SM, Devidas M, et al.: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005, 23:3376-3382.
19. Gandhi V, Kilpatrick JM, Plunkett W, et al.: A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005, 106:4253-4260.
20. Korycka A, Blonski JZ, Robak T: Forodesine (BCX-1777, Immucillin H)-a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007, 7:976-983.
21. Furman RR, Gore L, Ravandi F, Hoelzer D: Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a phase II study (interim report) [abstract]. Blood 2006, 108:524a.
22. Duval M, Suciu S, Ferster A, et al.: Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002, 99:2734-2739.
23. Rizzari C, Zucchetti M, Conter V, et al.: L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000, 11:189-193.
24. Moghrabi A, Levy DE, Asselin B, et al.: Results of the Dana-Farber Cancer Institute ALL Consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007, 109:896-904.
25. Wetzler M, Sanford BL, Kurtzberg J, et al.: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007, 109:4164-4167.
26. Douer D, Yampolsky H, Cohen LJ, et al.: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007, 109:2744-2750.
27. O'Connor OA: Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006, 18:591-597.
28. O'Connor OA, Hamlin PA, Portlock C, et al.: Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007, 139:425-428.
29. Giles F, Rizzieri DA, George S, et al.: A phase I study of Talvesta (talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome [abstract]. Blood 2006, 108:556a.
30. Thomas DA, Faderl S, O'Brien S, et al.: Chemoimmuno-therapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569-1580.
31. Gokbuget N, Hoelzer D: Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004, 83:201-205.
32. Strauss SJ, Morschhauser F, Rech J, et al.: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006, 24:3880-3886.
33. Rodig SJ, Abramson JS, Pinkus GS, et al.: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174-7179.
34. Tibes R, Keating MJ, Ferrajoli A, et al.: Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006, 106:2645-2651.
35. Piccaluga PP, Martinelli G, Malagola M, et al.: Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leuk Lymphoma 2004, 45:731-733.
36. Lozanski G, Sanford B, Mrozek K, et al.: Quantitative measurement of CD52 expression and alemtuzumab binding in adult acute lymphoblastic leukemia (ALL): correlation with immunophenotype and cytogenetics in patients (pts) enrolled on a phase I/II trial from the Cancer and Leukemia Group B (CALGB 10102) [abstract]. Blood 2007, 10:704a.
37. Gelmon KA, Tolcher A, Diab AR, et al.: Phase I study of liposomal vincristine. J Clin Oncol 1999, 17:697-705.
38. Sarris AH, Hagemeister F, Romaguera J, et al.: Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000, 11:69-72.
39. Thomas DA, Sarris AH, Cortes J, et al.: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 2006, 106:120-127.
40. Offidani M, Corvatta L, Centurioni R, et al.: High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J 2003, 4:47-53.
41. Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.J Clin Oncol 1999, 17:3110-3116.
42. Jabbour E, O'Brien S, Kantarjian H, et al.: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109:3214-3218.
43. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965-1971.
44. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
45. Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460-466.
46. Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469-1477.
47. Carpenter PA, Snyder DS, Flowers ME, et al.: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
48. Lee S, Kim DW, Kim YJ, et al.: Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003, 102:3068-3070.
49. Pfeifer H, Wassmann B, Pavlova A, et al.: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007, 110:727-734.
50. Ottmann OG, Larson RA, Kantarjian H, et al.: Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib [abstract]. Blood 2007, 118:828a.
51. Porrka K, Simonsson B, Dombret H, et al.: Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015) [abstract]. Blood 2007, 118:826a.
52. Ravandi F, Thomas D, Kantarjian H, et al.: Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 2007, 110:828a.
53. Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2007, 118:225a.
54. Kantarjian HM, Cortes J, le Coutre P, et al.: A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [abstract]. Blood 2007, 118:144a.
55. Leis JF, Stepan DE, Curtin PT, et al.: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004, 45:695-698.
56. Pfeifer H, Wassmann B, Hofmann WK, et al.: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003, 9:4674-4681.
57. Armstrong SA, Staunton JE, Silverman LB, et al.: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47.
58. DeAngelo DJ, Stone RM, Heaney ML, et al.: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108:3674-3681.
59. Smith BD, Levis M, Beran M, et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
60. Stone RM, DeAngelo DJ, Klimek V, et al.: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
61. Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
62. DeAngelo DJ, Stone RM, Silverman LB, et al.: A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [abstract]. J Clinical Oncol 2006, 24:357a.
63. Real PJ, Tosello V, Ai W, et al.: Inhibition of NOTCH1 signaling reverses glucocorticoid resistance in T-ALL [abstract]. Blood 2007, 110:52a.
64. Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.